Chromatography
Screening for Nitrosamines in Pharmaceutical Products
Feb 24 2020
Nitrosamine are carcinogenic compounds so need to be monitored to ensure unsafe levels are not found in consumer products. Due to unsafe levels being found in a number of pharmaceutical products the EMA (European Medicines Agency) is requiring pharmaceutical companies to complete and submit a risk assessment by 26th March. This means many pharmaceutical manufacturers will potentially need to screen their products for nitrosamine content.
The Ellutia 800 Series TEA is perfectly suited to nitrosamine detection thanks to is selectivity and sensitivity for Nitroso compounds. For testing of pharmaceutical drugs, The 800 Series TEA can be interfaced to a chemical stripping system that allows for rapid testing of ATNC (Apparent Total N-nitrosamine content). This quickly gives an accurate result for the total nitrosamine content of a sample showing both volatile and non-volatile components.
Any positive sample can then be further analysed by an 800 Series TEA interfaced to a GC where volatile nitrosamines such as NDMA (N-Nitrosodimethylamine) can be separated and quantified.
More information online
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark
Aug 28 2024 Phnom Penh, Cambodia
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK